We serve Chemical Name:lead(2+),diperchlorate CAS:13637-76-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:lead(2+),diperchlorate
CAS.NO:13637-76-8
Synonyms:Lead perchlorate,solid or solution;Lead diperchlorate;Lead perchlorate;UN1470;EINECS 237-125-7
Molecular Formula:Cl2O8Pb
Molecular Weight:406.10100
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:148.54000
Exact Mass:405.87400
LogP:0.04780
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 1470
Packing Group:II
Contact us for information like Lead perchlorate,solid or solution chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 237-125-7 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 237-125-7 Use and application,Lead perchlorate technical grade,usp/ep/jp grade.
Related News: SARS-CoV-2 has evolved mutations that severely compromise the neutralizing activities of multiple IgG monoclonal antibodies, including those under clinical trials and authorized for emergency use.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. 2-[(4-chloro-2-nitrophenyl)diazenyl]-N-(4-methoxyphenyl)-3-oxobutanamide manufacturers CHMP also recommended for approval Sanofi and Genzyme’s new Pompe disease drug, known in Europe as Nexviadyme (avalglucosidase alfa). Pompe disease is a rare, inherited disorder caused by the buildup of glycogen in the body’s cells. 5-(2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)-4-((2-(trifluoromethyl)benzyl)thio)pyrimidine suppliers For category of products which involve fermentation technologies, incentive is 20 per cent of the approved sales price. The government has put a cap of Rs. 10 crore per product per annum for five years. This is a seven year scheme from 2023-24 going up to 2029-30. Pyridinium,4-(3-cyclohexen-1-yl)-1-[2-[2-[2-[3-[(4R,5R)-3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]ethoxy]ethoxy]ethyl]-, iodide, rel- vendor & factory.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. 2-[(4-chloro-2-nitrophenyl)diazenyl]-N-(4-methoxyphenyl)-3-oxobutanamide manufacturers CHMP also recommended for approval Sanofi and Genzyme’s new Pompe disease drug, known in Europe as Nexviadyme (avalglucosidase alfa). Pompe disease is a rare, inherited disorder caused by the buildup of glycogen in the body’s cells. 5-(2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)-4-((2-(trifluoromethyl)benzyl)thio)pyrimidine suppliers For category of products which involve fermentation technologies, incentive is 20 per cent of the approved sales price. The government has put a cap of Rs. 10 crore per product per annum for five years. This is a seven year scheme from 2023-24 going up to 2029-30. Pyridinium,4-(3-cyclohexen-1-yl)-1-[2-[2-[2-[3-[(4R,5R)-3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]ethoxy]ethoxy]ethyl]-, iodide, rel- vendor & factory.
